Literature DB >> 22345377

Legal and organizational aspects of remote cardiac monitoring: the example of implantable cardioverter defibrillators.

Imgard Vinck1, Chris De Laet, Serge Stroobandt, Hans Van Brabandt.   

Abstract

The remote monitoring of implantable cardioverter defibrillators (ICDs) recently emerged as an attractive technological innovation that proved to be reasonably safe in partially replacing the in-clinic follow-ups of ICD patients with no or only mild symptoms. Apart from the fact that strong evidence about any additional clinical benefits and/or cost-efficiency are still awaited, legal and organizational hurdles remain in place, hampering any possibility for adoption of remote cardiac monitoring. This paper identifies a number of legal and organizational constraints which urgently need to be addressed. An elaboration of the specific juridical guidance for the interpretation and application of the relevant legislation is called for.

Entities:  

Mesh:

Year:  2012        PMID: 22345377     DOI: 10.1093/europace/eus004

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

Review 1.  Updates in medical professional liability: a primer for electrophysiologists.

Authors:  Christopher Austin; Fred Kusumoto
Journal:  J Interv Card Electrophysiol       Date:  2018-10-01       Impact factor: 1.900

2.  Barriers to Creating Scalable Business Models for Digital Health Innovation in Public Systems: Qualitative Case Study.

Authors:  Leah Taylor Kelley; Jamie Fujioka; Kyle Liang; Madeline Cooper; Trevor Jamieson; Laura Desveaux
Journal:  JMIR Public Health Surveill       Date:  2020-12-10

3.  Quarterly vs. yearly clinical follow-up of remotely monitored recipients of prophylactic implantable cardioverter-defibrillators: results of the REFORM trial.

Authors:  Gerhard Hindricks; Christian Elsner; Christopher Piorkowski; Milos Taborsky; Jan Christoph Geller; Burghard Schumacher; Jan Bytesnik; Hans Kottkamp
Journal:  Eur Heart J       Date:  2013-07-18       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.